Legal & General Group Plc reduced its stake in Teva Pharmaceutical Industries Limited (NYSE:TEVA - Free Report) by 34.9% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 3,250,262 shares of the company's stock after selling 1,740,342 shares during the quarter. Legal & General Group Plc owned 0.29% of Teva Pharmaceutical Industries worth $71,636,000 at the end of the most recent reporting period.
Other institutional investors also recently bought and sold shares of the company. Diversify Advisory Services LLC boosted its stake in shares of Teva Pharmaceutical Industries by 2.5% during the 4th quarter. Diversify Advisory Services LLC now owns 20,355 shares of the company's stock worth $426,000 after acquiring an additional 496 shares in the last quarter. Sanctuary Advisors LLC grew its position in shares of Teva Pharmaceutical Industries by 1.9% in the third quarter. Sanctuary Advisors LLC now owns 35,129 shares of the company's stock valued at $601,000 after purchasing an additional 664 shares during the period. Thrivent Financial for Lutherans lifted its holdings in shares of Teva Pharmaceutical Industries by 0.3% during the 4th quarter. Thrivent Financial for Lutherans now owns 225,210 shares of the company's stock worth $4,964,000 after acquiring an additional 699 shares during the period. Metis Global Partners LLC boosted its holdings in shares of Teva Pharmaceutical Industries by 6.7% in the 4th quarter. Metis Global Partners LLC now owns 13,697 shares of the company's stock valued at $302,000 after purchasing an additional 860 shares during the last quarter. Finally, DGS Capital Management LLC grew its position in Teva Pharmaceutical Industries by 6.8% during the third quarter. DGS Capital Management LLC now owns 13,627 shares of the company's stock valued at $246,000 after acquiring an additional 872 shares during the period. 54.05% of the stock is owned by institutional investors and hedge funds.
Teva Pharmaceutical Industries Stock Down 0.1 %
NYSE:TEVA traded down $0.02 on Tuesday, hitting $13.59. 7,201,630 shares of the company's stock traded hands, compared to its average volume of 9,908,671. The firm has a 50-day moving average price of $15.71 and a 200-day moving average price of $17.79. The company has a current ratio of 0.98, a quick ratio of 0.75 and a debt-to-equity ratio of 2.97. The company has a market cap of $15.40 billion, a PE ratio of -9.37, a price-to-earnings-growth ratio of 1.44 and a beta of 0.72. Teva Pharmaceutical Industries Limited has a 1 year low of $12.47 and a 1 year high of $22.80.
Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last released its earnings results on Wednesday, January 29th. The company reported $0.70 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.69 by $0.01. Teva Pharmaceutical Industries had a negative net margin of 9.91% and a positive return on equity of 42.46%. Equities analysts anticipate that Teva Pharmaceutical Industries Limited will post 2.5 EPS for the current fiscal year.
Analyst Upgrades and Downgrades
TEVA has been the topic of several research reports. Bank of America cut their price target on shares of Teva Pharmaceutical Industries from $23.00 to $20.00 and set a "buy" rating on the stock in a report on Thursday, March 6th. Barclays reduced their target price on shares of Teva Pharmaceutical Industries from $28.00 to $26.00 and set an "overweight" rating on the stock in a report on Thursday, January 30th. UBS Group lowered their price target on Teva Pharmaceutical Industries from $30.00 to $27.00 and set a "buy" rating for the company in a report on Thursday, January 30th. StockNews.com downgraded Teva Pharmaceutical Industries from a "buy" rating to a "hold" rating in a research report on Monday. Finally, Piper Sandler raised their target price on Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the company an "overweight" rating in a report on Friday, January 17th. Two research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. According to MarketBeat, Teva Pharmaceutical Industries presently has an average rating of "Moderate Buy" and a consensus price target of $23.43.
Check Out Our Latest Report on Teva Pharmaceutical Industries
About Teva Pharmaceutical Industries
(
Free Report)
Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.
Further Reading
Before you consider Teva Pharmaceutical Industries, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Teva Pharmaceutical Industries wasn't on the list.
While Teva Pharmaceutical Industries currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Like this article? Share it with a colleague.
Link copied to clipboard.
